Use of bivalirudin for anticoagulation in pediatric extracorporeal membrane oxygenation (ECMO)

Abstract

This study describes the use of bivalirudin in children on extracorporeal membrane oxygenation (ECMO). Pediatric patients receiving bivalirudin were compared to patients receiving heparin as the anticoagulant on ECMO. Data was collected for children under 18 years of age supported by ECMO from January 2016 to December 2019. Data collected included demographics, diagnosis, ECMO indication, type, and duration, indication for bivalirudin use, dose range, activated partial thromboplastin time (aPTT) levels, minor and major bleeding, hemolysis, and mortality. Forty pediatric patients received ECMO; eight received bivalirudin primarily for anticoagulation. The median age was 4 months (IQR 0.5, 92) in the heparin cohort, 0.6 months (IQR 0.0, 80.0) in the primary bivalirudin cohort. The indication for ECMO was respiratory in 5 patients (18%) in the heparin group versus 6 (75%) in the primary bivalirudin group, cardiac in 18 (67%) in heparin versus 1 (12.5%) in primary bivalirudin, and extracorporeal-cardiopulmonary resuscitation (E-CPR) in 4 (15%) in heparin versus 1 (12.5%) in primary bivalirudin. Bivalirudin was the initial anticoagulant for eight patients (66.6%) while three (25%) were switched due to concern for heparin-induced thrombocytopenia (HIT) and one (8%) for heparin resistance. The median time to achieve therapeutic aPTT was 14.5 hours compared to 12 hours in the heparin group. Sixty-five percent of aPTT values in the bivalirudin and 44% of values in the heparin group were in the therapeutic range in the first 7 days. Patients with primary bivalirudin use had significantly lower dose requirement at 12 (p = 0.003), 36 (p = 0.007), and 48 (p = 0.0002) hours compared to patients with secondary use of bivalirudin. One patient (12.5%) had major bleeding, and two patients (25%) required circuit change in the primary bivalirudin cohort. Bivalirudin may provide stable and successful anticoagulation in children. Further large, multicenter studies are needed to confirm these findings.

Keywords

bivalirudin extracorporeal membrane oxygenation (ECMO)anticoagulation bleeding

Get full access to this article

View all access options for this article.

References

Bembea

Annich

Rycus

, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14(2): e77–e84.

Dalton

Reeder

Garcia-Filion

, et al. Factors associated with bleeding and thrombosis in children receiving extracorporeal membrane oxygenation. Am J Respir Crit Care Med 2017; 196(6): 762–771.

Warkentin

Greinacher

Koster

Bivalirudin. Thromb Haemost 2008; 99(5): 830–839.

Di Nisio

Middeldorp

Buller

. Direct thrombin inhibitors. N Engl J Med 2005; 353(10): 1028–1040.

Buck

ML.

Bivalirudin as an alternative to heparin for anticoagulation in infants and children. J Pediatr Pharmacol Ther 2015; 20(6): 408–417.

Robson

The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000; 12(Suppl F): 33F–33F6.

Nagle

Dager

Duby

, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med 2013; 14(4): e182–e188.

Ranucci

Ballotta

Kandil

, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15(6): R275.

Schill

Douds

Burns

, et al. Is anticoagulation with bivalirudin comparable to heparin for pediatric extracorporeal life support? Results from a high-volume center. Artif Organs 2021; 45(1): 15–21.

10.

Hamzah

Jarden

Ezetendu

, et al. Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2020; 21(9): 827–834.

11.

O’Halloran

Andren

Mecklosky

, et al. Mortality and factors associated with hemorrhage during pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2020; 21(1): 75–81.

12.

Dalton

Garcia-Filion

Holubkov

, et al. Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr Crit Care Med 2015; 16(2): 167–174.

13.

Kaseer

Soto-Arenall

Sanghavi

, et al. Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. J Card Surg 2020; 35(4): 779–786.

14.

Pieri

Agracheva

Bonaveglio

, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013; 27(1): 30–34.

15.

Berei

Lillyblad

Wilson

, et al. Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation. ASAIO J 2018; 64(5): 623–629.

16.

Andrew

Paes

Milner

, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70(1): 165–172.

17.

Stansfield

Wise

Ham

3rd , et al. Outcomes following routine antithrombin III replacement during neonatal extracorporeal membrane oxygenation. J Pediatr Surg 2017; 52(4): 609–613.

18.

Wong

Nguyen

Shah

, et al. Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: a multicenter cohort study. Pediatr Crit Care Med 2016; 17(12): 1170–1178.

19.

ECLS Registry Report International Summary–April 2021. Ann Arbor, MI: ELSO Edition (2021) https://www.elso.org/Registry/Statistics/InternationalSummary.aspx April 2021.

20.

Walker

Roberts

Louie

, et al. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy. ASAIO J 2019; 65(2): 134–138.

21.

Pappalardo

Agracheva

Covello

, et al. Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step? J Cardiothorac Vasc Anesth 2014; 28(4): 1013–1017.

22.

Koster

Weng

Bottcher

, et al. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg 2007; 83(5): 1865–1867.